Core Viewpoint - Highwoods Properties, Inc. is set to release its first quarter 2026 financial results on April 28, 2026, with a conference call scheduled for April 29, 2026, at 11:00 A.M. Eastern time [1]. Company Overview - Highwoods Properties, Inc. is a publicly-traded real estate investment trust (REIT) based in Raleigh, focusing on owning, developing, acquiring, leasing, and managing properties in prime business districts across several major cities including Atlanta, Charlotte, Dallas, Nashville, Orlando, Raleigh, Richmond, and Tampa [3]. - The company's vision is to lead the evolution of commercial real estate, aiming to create environments that inspire collaboration and achievement among customers and their teams, ultimately delivering greater value to shareholders [3]. Conference Call Details - For US/Canada participants, the conference call can be accessed by dialing (800) 715-9871 with access code 4441285, while international callers should use (646) 307-1963 with the same passcode [2]. - A live webcast of the call will be available on the company's website, and a replay will also be accessible post-call [2].

Core Insights - Ethos has expanded its partnership with Banner Life Insurance Company to introduce two new whole life insurance products, Simplified Issue Whole Life and Guaranteed Issue Whole Life, through its technology platform, enhancing access to life insurance for families across the U.S. [1][2][3] Company Overview - Ethos is a leading life insurance technology company focused on democratizing access to life insurance, utilizing a robust technology platform that simplifies the purchasing process by eliminating medical exams and requiring only a few health questions [4]. - Banner Life Insurance Company, established in 1949, provides term life insurance and is dedicated to enhancing its product offerings and customer experience, with a high claim payment rate of 99% for term life insurance [5]. Product Expansion - The collaboration between Ethos and Banner Life has resulted in the launch of two new whole life insurance products, increasing Ethos' product portfolio to a total of 12 offerings [3]. - The new products aim to provide affordable permanent protection for end-of-life expenses, thereby addressing the life insurance coverage gap in the U.S. [2][3]. Technology and Market Reach - Ethos has developed one of the most advanced technology platforms in the life insurance sector, enabling carrier partners like Banner Life to access new markets and improve policyholder experiences [2]. - The new whole life insurance products will initially be available through select agencies, further extending the reach of both companies [3].

Core Insights - BioCardia, Inc. reported its financial results for the year ended December 31, 2025, highlighting advancements in its CardiAMP and CardiALLO cell therapies for cardiovascular diseases [1][9][14]. Financial Performance - The company had no revenues in 2025, down from $58,000 in 2024, primarily due to the fulfillment of performance obligations [16]. - Research and development expenses increased to approximately $5.0 million in 2025 from $4.4 million in 2024, driven by activities related to the CardiAMP Heart Failure Trial [16]. - Selling, general and administrative expenses decreased to approximately $3.3 million in 2025 from $3.7 million in 2024 [16]. - The net loss for 2025 was approximately $8.2 million, compared to $7.9 million in 2024 [16]. Clinical Developments - The CardiAMP autologous cell therapy for ischemic heart failure is advancing regulatory discussions with the FDA and Japan's PMDA, alongside the confirmatory CardiAMP HF II Trial [3][5]. - Positive results from the CardiAMP trial showed an average increase of 107 seconds in exercise tolerance and an 82% reduction in angina episodes at the six-month follow-up [4]. - The company is preparing to submit a Q-Sub request to the FDA regarding the CardiAMP System's approvability based on safety and efficacy signals from clinical trials [5][10]. Upcoming Milestones - Anticipated milestones include the CardiAMP for Ischemic HFrEF FDA Q-Sub on Approval Pathway in Q1 2026 and a formal clinical consultation with Japan's PMDA in Q2 2026 [16]. - An oral presentation of CardiAMP for Chronic Myocardial Ischemia is scheduled for Euro PCR in Q2 2026 [16]. - A Pre-Submission meeting with the FDA regarding the Helix transendocardial delivery system is also planned for Q2 2026 [10][16]. Company Overview - BioCardia is focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with its main platforms being CardiAMP and CardiALLO cell therapies [14]. - The company utilizes its Helix biotherapeutic delivery system and Morph vascular navigation product platforms to enhance treatment efficacy [14].

Core Insights - Avista Utilities has received formal approval from the Washington Utilities and Transportation Commission for its 2025 Clean Energy Implementation Plan (CEIP), which aims to meet Washington's non-carbon emitting energy requirements [1][2][3] Group 1: Clean Energy Goals - The 2025 CEIP outlines Avista's commitment to providing carbon neutral electricity by 2030 and achieving a 100% clean energy supply by 2045, in alignment with the Clean Energy Transformation Act (CETA) [3][4] - The plan includes measurable actions to accelerate the clean energy transition, building on a system where over half of Avista's generating potential already comes from renewable sources such as hydropower, biomass, wind, and solar [4][10] Group 2: Implementation Strategies - The CEIP serves as a four-year action plan that translates the long-term energy strategy from Avista's Integrated Resource Plan (IRP) into specific commitments, including a 2025 Request for Proposals (RFP) for new energy resources [2][3] - Key elements of the plan include increased clean energy delivery targets for Washington customers from 2026 to 2029, advancements in modern grid management, expanded energy efficiency programs, and enhanced community engagement commitments [10] Group 3: Community and Customer Focus - The plan emphasizes community involvement and aims to address energy and environmental inequities through initiatives like the Named Communities Investment Fund (NCIF) [10] - Avista's service area covers 34,000 square miles, providing energy services to 429,000 customers and natural gas to 386,000 customers, with a total population of 1.5 million [8]

Summary of Key Points Core Viewpoint - The total short interest in Nasdaq securities has increased, indicating a growing bearish sentiment among investors as of March 13, 2026 Group 1: Nasdaq Global Market - Short interest in 3,657 Nasdaq Global Market securities totaled 16,179,628,406 shares, up from 15,794,218,322 shares in the previous reporting period [1] - The mid-March short interest represents an average of 2.42 days, a decrease from 2.64 days in the prior reporting period [1] Group 2: Nasdaq Capital Market - Short interest in 1,649 securities on The Nasdaq Capital Market totaled 3,792,945,487 shares, compared to 3,685,699,100 shares in the previous reporting period [2] - This represents an average daily volume of 1.23 days, down from 1.65 days in the previous reporting period [2] Group 3: Overall Nasdaq Securities - Total short interest in all 5,306 Nasdaq securities reached 19,972,573,893 shares, an increase from 19,479,917,422 shares in the previous reporting period [3] - The average daily volume for this total is 2.05 days, compared to 2.37 days in the prior reporting period [3] Group 4: Short Sale Definition - A short sale is defined as the sale of a security that the seller does not own or any sale consummated by the delivery of a borrowed security [4]

Core Insights - Reed's, Inc. has announced financial results for Q4 and FY 2025, showing a sequential improvement in net sales and gross margin despite a net loss [2][12] - Neal Cohane has been appointed as interim CEO following the departure of former CEO Cyril Wallace, with a search for a permanent CEO underway [2][5] Leadership Transition - Neal Cohane brings extensive experience in the beverage industry, having previously served as COO and chief sales officer at Reed's, and has a strong background in scaling beverage brands [3][4] - The board expresses confidence in Cohane's ability to lead the company through its next growth phase [5][6] Financial Performance - Q4 2025 net sales were $7.5 million, down from $9.7 million in Q4 2024, primarily due to lower volumes with national customers [11][13] - Gross profit for Q4 2025 was $1.5 million, with a gross margin of 20%, compared to $2.9 million and 30% in the prior year [11][14] - FY 2025 net sales totaled $34.1 million, down from $38.0 million in FY 2024, with a net loss of $15.8 million compared to $13.2 million in the previous year [11][12] Cost Management - Delivery and handling costs decreased by 35% to $1.1 million in Q4 2025, and selling, general, and administrative expenses were reduced by 19% to $4.0 million [15][11] - The company is focused on operational efficiency and cost optimization to support sustainable growth [12][6] Strategic Initiatives - Reed's aims to leverage its in-house sales team and outsourced brokers to expand customer reach and shelf space [12] - The company plans to invest in brand marketing, product innovation, and expand its distribution network, particularly in Asia [12][6] Liquidity and Cash Flow - As of December 31, 2025, Reed's had approximately $10.4 million in cash and $9.3 million in total debt, showing stability in liquidity compared to the previous year [17][11] - Cash used in operations for Q4 2025 was $3.8 million, slightly improved from $3.9 million in the year-ago period [17]

Core Insights - MaxCyte, Inc. reported total revenue of $7.3 million for Q4 2025, which is at the top of the previously announced range, and full-year revenue of $33.0 million, also at the top of the range [1][13] - The company expects 2026 revenue to be between $30 million and $32 million, with core revenue projected at $25 million to $27 million and SPL Program-related revenue at approximately $5 million [1][20] Financial Performance - Q4 2025 total revenue decreased by 16% compared to Q4 2024, while core business revenue fell by 22% in the same period [7][9] - For the full year 2025, total revenue decreased by 15% compared to 2024, with core business revenue down by 9% [13][14] - Gross profit for Q4 2025 was $5.7 million, representing a gross margin of 78%, compared to a gross margin of 74% in Q4 2024 [10] - The company reported a net loss of $9.6 million for Q4 2025, an improvement from a net loss of $10.6 million in Q4 2024 [12] Strategic Developments - In 2025, MaxCyte signed 4 new SPL agreements and aims to expand its sales pipeline across its ExPERT electroporation platform and SeQure assay services [3] - The company anticipates supporting up to four therapies in Phase III by the end of 2026, having already received a milestone payment for one of these therapies [3] Cash Position - As of December 31, 2025, total cash, cash equivalents, and investments were $155.6 million, with expectations to end 2026 with at least $136 million [1][16]

Core Viewpoint - TELA Bio, Inc. reported strong financial results for Q4 and full year 2025, with significant revenue growth and improved gross margins, while maintaining flat operating expenses, indicating operational leverage and confidence in future growth [3][4][8]. Financial Performance - Q4 2025 revenue reached $20.9 million, an 18% increase from Q4 2024, driven by new customer additions, the U.S. launch of a larger OviTex PRS product, and increased international sales [4][10]. - Full year 2025 revenue totaled $80.3 million, a 16% increase compared to 2024, attributed to similar factors as the quarterly growth [8][10]. - Gross profit for Q4 2025 was $13.8 million, representing 65.9% of revenue, up from 63.6% in Q4 2024, primarily due to lower inventory-related expenses [5][10]. - For the full year 2025, gross profit was $54.3 million, or 67.7% of revenue, compared to 67.1% in 2024, reflecting improved inventory cost management [9][11]. Operating Expenses and Losses - Operating expenses in Q4 2025 were $20.4 million, slightly higher than $19.6 million in Q4 2024, driven by increased compensation costs and higher study and professional fees [6][10]. - The loss from operations for Q4 2025 was $6.6 million, an improvement from a loss of $8.4 million in Q4 2024 [7][10]. - For the full year 2025, the loss from operations was $33.8 million, a slight improvement from $34.1 million in 2024 [11][12]. Cash Position and Debt - As of December 31, 2025, TELA Bio had cash and cash equivalents of $50.8 million, down from $52.7 million in 2024 [12][19]. - The company closed a credit facility for up to $70 million, which includes an initial loan of $60 million, aimed at supporting future growth [10]. Future Outlook - TELA Bio anticipates at least 8% revenue growth in 2026, with first quarter revenue projected at approximately $18.5 million [16]. - The company has strengthened its sales force to 89 revenue-generating representatives, enhancing its market penetration capabilities [3][10].

Core Insights - Absci Corporation has successfully dosed the first three cohorts in the single ascending dose (SAD) portion of its ongoing Phase 1/2a HEADLINE trial for ABS-201, which has shown favorable emerging safety data [1][5] - The company appointed Dr. Ransi Somaratne as Chief Medical Officer to lead clinical execution and strategy [1][2] - Absci's cash, cash equivalents, and marketable securities are sufficient to fund operations into the first half of 2028 [1][7] Clinical Development - ABS-201 is being developed for androgenetic alopecia (AGA) and endometriosis, addressing significant unmet medical needs in both areas [2][6] - The company plans to deliver interim proof-of-concept data for ABS-201 in the second half of 2026 and initiate a Phase 2 trial for endometriosis by year-end 2026 [2][6] - ABS-201 has demonstrated the ability to stimulate hair growth and regenerate the follicle stem cell niche, with significant inhibition of the PRLR signaling pathway [5][6] Financial Performance - For Q4 2025, Absci reported revenue of $0.7 million, unchanged from Q4 2024 [8] - Research and development expenses increased to $25.3 million in Q4 2025 from $18.4 million in Q4 2024, primarily due to advancements in internal programs [9] - The net loss for Q4 2025 was $29.6 million, compared to a net loss of $29.0 million in Q4 2024 [11] Annual Financial Results - For the full year 2025, Absci reported revenue of $2.8 million, down from $4.5 million in 2024 [12] - Research and development expenses rose to $81.4 million in 2025 from $63.9 million in 2024 [12] - The net loss for the full year 2025 was $115.2 million, compared to a net loss of $103.1 million in 2024 [15] Pipeline and Future Outlook - Absci continues to explore potential partnerships and outlicensing opportunities for its programs, including ABS-101 and ABS-301 [14] - The company anticipates signing one or more drug creation partnerships in 2026, including with a large pharmaceutical company [14]

Group 1 - Solana Company (NASDAQ: HSDT) will release its fourth quarter and full year operating results on March 30, 2026, after market close [1] - A conference call will be held on the same day at 4:30 p.m. Eastern Time to discuss the results and provide a business update [1] - The webcast of the conference call will be archived on the Company's investor relations website [1] Group 2 - Solana Company is a leading neurotech company focused on neurologic deficits using an orally applied technology platform [2] - The Company also operates a digital asset treasury dedicated to acquiring and holding Solana (SOL), aiming to maximize SOL per share through strategic capital market use [2] - The digital asset treasury was created in partnership with Pantera Capital and Summer Capital, providing public market investors exposure to Solana's growth [2]